Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study

Br J Haematol. 2022 Jan;196(2):448-452. doi: 10.1111/bjh.17800. Epub 2021 Aug 30.
No abstract available

Keywords: efficacy; eltrombopag; immune thrombocytopenia; rituximab; safety.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzoates / administration & dosage
  • Benzoates / adverse effects
  • Benzoates / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Humans
  • Hydrazines / administration & dosage
  • Hydrazines / adverse effects
  • Hydrazines / therapeutic use*
  • Molecular Targeted Therapy
  • Purpura, Thrombocytopenic, Idiopathic / diagnosis
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Purpura, Thrombocytopenic, Idiopathic / etiology
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Receptors, Thrombopoietin / antagonists & inhibitors
  • Retreatment
  • Rituximab / drug effects
  • Treatment Outcome

Substances

  • Benzoates
  • Hydrazines
  • Pyrazoles
  • Receptors, Thrombopoietin
  • Rituximab
  • eltrombopag